

**CORRIGENDUM TO THE NOTICE OF EXTRAORDINARY GENERAL MEETING**

This corrigendum is being issued to the Members of Concord Drugs Limited with reference to the Notice of Extraordinary General Meeting (“EGM”) dated July 09, 2025, which was circulated and filed with the stock exchange in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the EGM scheduled to be held on Thursday, July 31, 2025 at 10:30 A.M. IST, via Video Conferencing (VC)/Other Audio-Visual Means (OAVM).

Pursuant to the observations received from BSE Limited and in order to provide enhanced clarity and ensure compliance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR”) and SEBI LODR, the Company hereby issues this corrigendum to provide certain clarifications, corrections and updated disclosures in the EGM Notice without altering the substance or intent of the resolutions set out therein.

This corrigendum shall be deemed to form an integral part of the original EGM Notice and should be read in conjunction with the same. Except as specifically amended in this corrigendum, all other information and contents furnished in the original Notice shall remain unchanged.

Through this Corrigendum it is hereby notified to all the shareholders/members of the Company that in the said Notice of EGM

i) **The point 3 in respect of explanatory statement to Item-2 shall be read as follows:**

**Point- (3) Revised Purpose/Object of the Issue and Utilization of Funds**

The Company proposes to raise funds through the Preferential Allotment to strategic investors. The proceeds raised through the Preferential Issue (“Issue Proceeds”) will be utilized for the following specific purposes:

**1. To Strengthen Working Capital and Operational Requirements – ₹4.32 Cr (37.5%)**

- Procurement of raw materials and APIs for uninterrupted production
- Timely payment to vendors and supply chain management
- Expenses related to marketing, distribution, and logistics
- Utilities and recurring overheads related to manufacturing

**Deployment Timeline:** In a phased manner over 12–15 months from receipt of funds.

**2. Upgradation of Manufacturing Facilities in Compliance with Revised Schedule M – cGMP 2022 – ₹4.32 Cr (37.5%)**

In line with the Ministry of Health and Family Welfare’s revised Schedule M – Good Manufacturing Practices (cGMP) 2022 guidelines, the Company intends to upgrade its existing facilities to comply with regulatory, Funds will be utilized for:

- Purchase and installation of cGMP-compliant machinery and equipment
- Enhancement of cleanrooms and HVAC systems
- Implementation of automation and IT systems (e.g., QMS, LIMS)
- Training of staff in line with new cGMP guidelines
- Required structural and civil improvements

**Deployment Timeline:** In a phased manner over 12–15 months from receipt of funds.

**3. General Corporate Purpose – ₹2.88 Cr (25%)**

- Support for administrative expansion
- Legal and professional expenses
- Technology upgrades not directly linked to cGMP
- Business development and regulatory consulting for global approvals (e.g., WHO-GMP, PIC/S)

**Deployment Timeline:** Within 12–15 months (phased) from receipt of funds.

Sl. No	Particulars	Amount (₹)	% of Total Issue	Deployment Timeline
1	Working Capital and Operational Support	4,32,19,687.50	37.5%	Within 12–15 months (phased)
2	Upgradation of Manufacturing Facilities (Schedule M – cGMP 2022 Compliance)	4,32,19,687.50	37.5%	Within 12–15 months (phased)
3	General Corporate Purposes	2,88,13,125	25.0%	Within 12–15 months (phased)
<b>Total</b>		<b>11,52,52,500</b>	<b>100%</b>	

**ii) The point 3 in respect of explanatory statement to Item-3 shall be read as follows:**

**Item-3 of Explanatory statement Revised Purpose/Object of the Issue and Utilization of Funds**

The Company proposes to raise funds through the Preferential Allotment to strategic investors. The proceeds raised through the Preferential Issue (“Issue Proceeds”) will be utilized for the following specific purposes:

### 1. To Strengthen Working Capital and Operational Requirements - ₹ 2.75 Cr (37.5%)

- Procurement of raw materials and APIs for uninterrupted production
- Timely payment to vendors and supply chain management
- Expenses related to marketing, distribution, and logistics
- Utilities and recurring overheads related to manufacturing

Deployment Timeline: In a phased manner over 12–15 months from receipt of funds.

### 2. Upgradation of Manufacturing Facilities in Compliance with Revised Schedule M - cGMP 2022 - ₹2.75 Cr (37.5%)

In line with the Ministry of Health and Family Welfare’s revised Schedule M - Good Manufacturing Practices (cGMP) 2022 guidelines, the Company intends to upgrade its existing facilities to comply with regulatory, Funds will be utilized for:

- Purchase and installation of cGMP-compliant machinery and equipment
- Enhancement of cleanrooms and HVAC systems
- Implementation of automation and IT systems (e.g., QMS, LIMS)
- Training of staff in line with new cGMP guidelines
- Required structural and civil improvements

Deployment Timeline: In a phased manner over 12–15 months from receipt of funds.

### 3. General Corporate Purpose - 1.83 Crs (25%)

- Support for administrative expansion
- Legal and professional expenses
- Technology upgrades not directly linked to cGMP
- Business development and regulatory consulting for global approvals (e.g., WHO-GMP, PIC/S)

Deployment Timeline: Within 12–15 months (phased) from receipt of funds.

Sl. No	Particulars	Amount (₹)	% of Total Issue	Deployment Timeline
1	Working Capital and Operational Support	2,75,65,312.50	37.5%	Within 12–15 months (phased)
2	Upgradation of Manufacturing Facilities (Schedule M - cGMP 2022 Compliance)	2,75,65,312.50	37.5%	Within 12–15 months (phased)

3	General Corporate Purposes	1,83,76,875	25.0%	Within 12-15 months (phased)
<b>Total</b>		<b>7,35,07,500</b>	<b>100%</b>	

iii) **The point 19 in respect of explanatory statement to Item-2 shall be read as follows:**

Sl.No	Name of the Proposed Allottee	Category	Ultimate Beneficial Owner	Pre-preferential Holding (Number of shares)	Pre-preferential holding (%)	No. of Equity Shares Proposed to be issued	Post-Issue holding (%) *
1	S. Nagi Reddy	Promoter	Self	28,60,536	28.61%	2,00,000	24.74%
2	S. Koni Reddy	Promoter	Self	950,543	9.51%	1,50,000	10.86%
3	S. Manoj Kumar Reddy	Promoter	Self	16,28,125	16.28%	1,50,000	15.32%
4	Anjana bangad	Public	Self	Nil	Nil	3,00,000	1.97%
5	Anuradha bangad	Public	Self	Nil	Nil	3,00,000	1.97%
6	Pranali bangad	Public	Self	Nil	Nil	3,00,000	1.97%
7	Vikas bangad	Public	Self	Nil	Nil	3,00,000	1.97%
8	C Sushmitha	Public	Self	Nil	Nil	11,00,000	7.24%
9	Komal sharma	Public	Self	Nil	Nil	2,00,000	1.32%
10	Mohan Thodupunuri	Public	Self	1,01,006	1.01%	50,000	0.99%
11	Sharada Kovuri	Public	Self	Nil	Nil	1,25,000	0.82%

(Post Preferential (%) shareholding is calculated considering both warrant allotment & equity shares all together).

iv) **The point 19 in respect of explanatory statement to Item-3 shall be read as follows:**

Sl. No	Name of the Proposed Allottee	Category	Ultimate Beneficial Owner	Pre-preferential Holding	Pre- Issue Shareholding (%)	Number of shares proposed to allotted	Post-Issue Shareholding*
--------	-------------------------------	----------	---------------------------	--------------------------	-----------------------------	---------------------------------------	--------------------------

1	S. Nagi Reddy	Promoter	Self	28,60,536	28.61%	7,00,000	24.74%
2	S. Koni Reddy	Promoter	Self	950,543	9.51%	550,000	10.86%
3	S. Manoj Kumar Reddy	Promoter	Self	16,28,125	16.28%	550,000	15.32%
4	Sheetal Sharma	Public	Self	Nil	Nil	225,000	1.48%

(Post Preferential (%) shareholding is calculated considering both warrant allotment & equity shares all together).

v) **The point 24 in respect of explanatory statement to Item-2 and 3 shall be read as follows:**

The certificate from M/s PSK & Associates. (Company Secretaries), certifying that the Preferential Issue is being made in accordance with the requirements contained in the SEBI ICDR Regulations shall be made available for inspection by the Members during the meeting and will also be made available on the Company's website along with pricing certificate.

Website Link for PCS Certificate for compliance and pricing

<https://concorddrugs.in/wp-content/uploads/2025/07/PCS-Compliance-Certificate-pdf>

<https://concorddrugs.in/wp-content/uploads/2025/07/PCS-Certificate.pdf>

(Official website of Concord Drugs Limited > Investor Relations > EGM 2025 > PCS Certificate)

A copy of this corrigendum is being placed on the Company's website at [www.concorddrugs.in](http://www.concorddrugs.in), and will also be disseminated to BSE Ltd. and available on its website.

For Concord Drugs Ltd

Sd/-

**S. Nagi Reddy**

(DIN: 01764665)

Chairman and Managing Director

**Date: 22.07.2025**

**Place: Hyderabad**